Provided by Tiger Trade Technology Pte. Ltd.

Monopar Therapeutics

54.10
-0.4600-0.84%
Post-market: 54.100.00000.00%16:10 EDT
Volume:184.32K
Turnover:10.24M
Market Cap:361.53M
PE:-18.10
High:57.47
Open:54.40
Low:53.84
Close:54.56
52wk High:105.00
52wk Low:26.06
Shares:6.68M
Float Shares:4.93M
Volume Ratio:1.03
T/O Rate:3.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9895
EPS(LYR):-4.1123
ROE:-14.22%
ROA:-10.39%
PB:2.62
PE(LYR):-13.16

Loading ...

Monopar Therapeutics CFO Quan Anh Vu Acquires Common Shares

Reuters
·
Dec 30, 2025

Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics

Simply Wall St.
·
Dec 21, 2025

Stock Track | Monopar Therapeutics Soars 8.74% on Bullish Analyst Rating and $130 Price Target

Stock Track
·
Nov 19, 2025

Stock Track | Monopar Therapeutics Soars 8.74% Following Analyst's Buy Rating and $130 Price Target

Stock Track
·
Nov 19, 2025

Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position

TIPRANKS
·
Nov 19, 2025

Monopar Therapeutics Shares Fall After Raymond James Downgrade

MT Newswires Live
·
Nov 15, 2025

Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade

Stock Track
·
Nov 14, 2025

BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Nov 14, 2025

Monopar Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 14, 2025

Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate

Benzinga
·
Nov 13, 2025

Monopar Therapeutics reports third quarter net loss of $3.4 million

Reuters
·
Nov 13, 2025

Press Release: Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

Dow Jones
·
Nov 13, 2025

Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data

TIPRANKS
·
Nov 10, 2025

Leerink Partners Initiates Coverage on Monopar Therapeutics With Outperform Rating, $115 Price Target

MT Newswires Live
·
Nov 10, 2025

Piper Sandler Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Nov 10, 2025

Monopar Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
Nov 10, 2025

Monopar Therapeutics Inc : Chardan Capital Markets Raises Target Price to $100 From $85

THOMSON REUTERS
·
Nov 10, 2025

Monopar presents new data, analyses from Phase 2 ALXN1840-WD-204 study

TIPRANKS
·
Nov 10, 2025

Monopar Therapeutics Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline

Reuters
·
Nov 09, 2025

BTIG Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Nov 06, 2025